VANCOUVER, May 10 /PRNewswire-FirstCall/ -- GeneMax Corp. (OTC Bulletin Board: GMXX; Frankfurt: GX1) Today, GeneMax Corp. announced that its patented TAP-1 anti-cancer technology is effective in generating immune responses against melanoma in mice. A recent article in the Journal of Immunology corroborates GeneMax's TAP-1 technology (Transporters Associated with Antigen Processing) that promotes an immune response that destroys these cancer cells. In this study, two leading edge vaccine approaches (adenovirus and dendritic cell-based) were tested for their efficacy against melanoma (skin cancer) cells. Experiments with both tumor vaccines demonstrated that introduction of TAP-1 to the melanoma cells increased the recognition and destruction of the cancer cells by the immune system. The article entitled "CTL-Dependent and -Independent Antitumor Immunity is Determined by the Tumor Not the Vaccine", can be found in the May 1, 2004 issue of the Journal of Immunology (reference 1;172(9):5200-5205).
Ronald L. Handford, President & CEO of GeneMax remarked, "Further corroboration of our core technology demonstrates the potential of GeneMax's TAP-1 cancer immunotherapy to affect a wide variety of cancers. These additional findings suggest that many cancer vaccines under development by a variety of universities and competing companies will not be maximally effective unless TAP-1 is expressed in the cancer cells. GeneMax's TAP-1 vaccine technology increases TAP expression in cancer cells making them visible to the immune system and allowing for their effective destruction. GeneMax's anti-cancer technology thus addresses a fundamental need in the field of cancer immunotherapies."
Collaborating authors of the article include Professor Wilfred Jefferies and Dr. Qian-Jin Zhang, of the Biomedical Research Centre and Biotechnology Laboratory at the University of British Columbia, Canada and Jaina Leitch, Dr. Yonghong Wan, Dr. Jonathan L. Bramson, Katie Fraser, Cecilia Lane, Dr. Kelley Putzu and Dr. Gosse J. Adema of McMaster University, Hamilton, Ontario, Canada. Professor Jefferies is GeneMax's Chairman and Chief Scientific Officer. The research that led to the scientific publication was supported by grants from the Canadian Institutes of Health Research (CIHR) and the Canadian Network for Vaccines and Immunotherapeutics (CANVAC), as well as funding from GeneMax through its Collaborative Research Agreement with The University of British Columbia.
About GeneMax Corp.: GeneMax Corp. is a biotechnology company specializing in the discovery and development of immunotherapeutics aimed at the treatment and eradication of cancer, and therapies for infectious diseases, autoimmune disorders and transplant tissue rejection. It is currently producing and testing a cancer vaccine in anticipation of clinical trials.
For further information:
Contact: Kendra Payne
Phone: Toll Free (866) 872-0077 or (604) 714-1225, Fax: (604) 331-0877
Stock Exchange Information: (Symbol: OTCBB - GMXX, Symbol FWB - GX1,
WKN: 645096, ISN: US36870Q1031)
SAFE HARBOR STATEMENT
THIS NEWS RELEASE INCLUDES FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS PRESS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR GENEMAX CORP. INCLUDE BUT ARE NOT LIMITED THE RISKS ASSOCIATED WITH PRODUCT DISCOVERY AND DEVELOPMENT AS WELL AS THE RISKS SHOWN IN GENEMAX'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE INFORMATION REGARDING GENEMAX. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH OBTAINING GOVERNMENT GRANTS, THE SUCCESS OF PRECLINICAL AND CLINICAL TRIALS, THE PROGRESS OF RESEARCH AND PRODUCT DEVELOPMENT PROGRAMS, THE REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS, FUTURE CAPITAL REQUIREMENTS, AND GENEMAX'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH ACTIVITIES. THERE CAN BE NO ASSURANCE THAT GENEMAX'S DEVELOPMENT EFFORTS WILL SUCCEED, THAT SUCH PRODUCTS WILL RECEIVE REQUIRED REGULATORY CLEARANCE, OR THAT EVEN IF SUCH REGULATORY CLEARANCE WERE RECEIVED, THAT SUCH PRODUCTS WOULD ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. GENEMAX DISCLAIMS ANY INTENT OR OBLIGATIONS TO UPDATE THESE FORWARD-LOOKING STATEMENTS."